Tebotelimab, a PD1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study

被引：0
|
作者：
Lu, Si
Chen, Yu
Fang, Meiyu
Zou, Zhengyun
Wu, Di
Luo, Zhiguo
Zhang, Jian
Chen, Jing
Huang, Gang
Pan, Hongming
Ren, Xiubao
Cheng, Ying
Su, Haichuan
Xin, Yuan
Hua, Qiong
Hou, Jianmei
Guo, Jun
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT208
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT208
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study (vol 31, pg 5340, 2024)
    Zager, Jonathan S.
    Orloff, Marlana
    Ferrucci, Pier Francesco
    Choi, Junsung
    Eschelman, David J.
    Glazer, Evan S.
    Ejaz, Aslam
    Howard, J. Harrison
    Richtig, Erika
    Ochsenreither, Sebastian
    Reddy, Sunil A.
    Lowe, Michael C.
    Beasley, Georgia M.
    Gesierich, Anja
    Bender, Armin
    Gschnell, Martin
    Dummer, Reinhard
    Rivoire, Michel
    Arance, Ana
    Fenwick, Stephen William
    Sacco, Joseph J.
    Haferkamp, Sebastian
    Weishaupt, Carsten
    John, Johnny
    Wheater, Matthew
    Ottensmeier, Christian H.
    ANNALS OF SURGICAL ONCOLOGY, 2024, : 8262 - 8263
  • [42] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
    Cao, Yanshuo
    Lu, Ming
    Sun, Yu
    Gong, Jifang
    Li, Jie
    Lu, Zhihao
    Li, Jian
    Zhang, Xiaotian
    Li, Yan
    Peng, Zhi
    Zhou, Jun
    Wang, Xicheng
    Shen, Lin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 779 - 789
  • [43] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
    Yanshuo Cao
    Ming Lu
    Yu Sun
    Jifang Gong
    Jie Li
    Zhihao Lu
    Jian Li
    Xiaotian Zhang
    Yan Li
    Zhi Peng
    Jun Zhou
    Xicheng Wang
    Lin Shen
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 779 - 789
  • [44] A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDY OF INCA32459, A BISPECIFIC ANTI-PD1 AND ANTI-LAG-3 ANTIBODY, IN PATIENTS WITH SELECT ADVANCED MALIGNANCIES
    Piha-Paul, Sarina
    Bourayou, Nawel
    Schaub, Richard
    Yang, Yan-ou
    Wei, Wendy
    Mayes, Patrick
    Gangadhar, Tara
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A756 - A756
  • [45] Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
    Brown, Jennifer
    Plummer, Ruth
    Bauer, Todd M.
    Anthony, Stephen
    Sarantopoulos, John
    De Vos, Filip
    White, Mike
    Schupp, Marco
    Ou, Ying
    Vaishampayan, Ulka
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 6
  • [46] Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
    Jennifer Brown
    Ruth Plummer
    Todd M. Bauer
    Stephen Anthony
    John Sarantopoulos
    Filip De Vos
    Mike White
    Marco Schupp
    Ying Ou
    Ulka Vaishampayan
    Experimental Hematology & Oncology, 6
  • [47] Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
    Deng, Li-Juan
    Zhou, Ke-Shu
    Liu, Li-Hong
    Zhang, Ming-Zhi
    Li, Zhi-Ming
    Ji, Chun-Yan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Su-Jun
    Zhang, Hui-Lai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Hai-Yan
    Cao, Jun-Ning
    Zhu, Zun-Min
    Hu, Jian-Da
    Zhang, Wei
    Jing, Hong-Mei
    Ding, Kai-Yang
    Zhang, Xiang-Yang
    Zhao, Ren -Bin
    Zhang, Bin
    Tian, Ya -Min
    Song, Yong-Ping
    Song, Yu-Qin
    Zhu, Jun
    BLOOD ADVANCES, 2023, 7 (16) : 4349 - 4357
  • [48] Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
    LANCET ONCOLOGY, 2023, 24 (04): : E145 - E145
  • [49] A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF ABEMACICLIB IN PATIENTS WITH RECURRENT OLIGODENDROGLIOMA: TRIALS IN PROGRESS
    Bagley, Stephen
    Nasrallah, MacLean
    O'Rourke, Donald
    Hussain, Jasmin
    Maloney-Wilensky, Eileen
    Prior, Timothy
    Brem, Steven
    Desai, Arati
    NEURO-ONCOLOGY, 2019, 21 : 219 - 219
  • [50] Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase., open-label, multicenter, dose escalation/expansion study.
    Bai, Xue
    Li, Mei
    Pu, Xingxiang
    Cheng, Ying
    Chen, Jing
    Jiang, Yu
    Chen, Xue
    Liu, Jingjing
    Fan, Li
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345